Cary Street Partners Financial LLC Buys Shares of 28,052 Novo Nordisk A/S (NYSE:NVO)

Cary Street Partners Financial LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 28,052 shares of the company's stock, valued at approximately $2,413,000.

A number of other institutional investors also recently made changes to their positions in the stock. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Transce3nd LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $39,000. Finally, Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 4.0 %

Novo Nordisk A/S stock opened at $66.32 on Wednesday. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a market capitalization of $297.63 billion, a PE ratio of 20.16, a PEG ratio of 0.90 and a beta of 0.65. The business's 50-day simple moving average is $70.60 and its 200-day simple moving average is $87.08.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research analyst reports. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.